【Abstract】 Objective T. observe the effects of zopiclone and estazolam on behavioral and psychological symptoms, cognitive impairments and adverse reactions in patients with Parkinson' s disease (PD) and sleep disorders. Methods 96 patients with PD and sleep disorders were divided into zopiclone group (study group, n= 48) and estazolam group (control group, n = 48). The sleep quality[PD Sleep Scale (PDSS) , Epworth Sleepiness Scale (ESS)], behavioral and psychological symptoms[Unified PD Rating Scale I ( UPDRSI)] and cognitive function [Lowenstein Occupational Therapy Cognitive Assessment(LOTCA)] and motor function[Fugl-Meyer motor function assessment(FMA)] were assessed in the two groups before treatment(Tl) and after 4 weeks of treatment(T2) , and the adverse reactions were observed. Results At T2, the PDSS score in the two groups was higher than that at T1 (P<0.05) , but there was no significant difference between the two groups(P〉0.05). The scores of LOTCA and FMA in the two groups was higher than that at T1, and the scores in study group were greater than those in control group(P<0.05). The scores of ESS and UPDRSI in the two groups were lower than those at T1, and the scores in study group were smaller than those in control group(P<0 05). The total adverse reaction rate was lower in study group than that in control group(P<0.05). Conclusions Zopiclone is superior to eszolam in improving sleep quality, behavioral and psychological symptoms, cognitive function and motor function in patients with PD and sleep disorders, and it has fewer adverse reactions and is more advantageous.